Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to -$1.28.

  • Janux Therapeutics' EPS (Weighted Average and Diluted) rose 23.53% to -$0.39 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.67, marking a year-over-year decrease of 43.97%. This contributed to the annual value of -$1.28 for FY2024, which is 3.03% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' EPS (Weighted Average and Diluted) is -$1.28, which was up 3.03% from -$1.32 recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' EPS (Weighted Average and Diluted) peaked at -$1.28 during FY2024, and registered a low of -$1.52 during FY2022.
  • Over the past 3 years, Janux Therapeutics' median EPS (Weighted Average and Diluted) value was -$1.32 (recorded in 2023), while the average stood at -$1.37.
  • In the last 5 years, Janux Therapeutics' EPS (Weighted Average and Diluted) dropped by 9.35% in 2022 and then grew by 13.16% in 2023.
  • Yearly analysis of 4 years shows Janux Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.39 in 2021, then fell by 9.35% to -$1.52 in 2022, then increased by 13.16% to -$1.32 in 2023, then increased by 3.03% to -$1.28 in 2024.